Thank you for the Registration! Please check your mailbox. Simply click on the button in your email and you are successfully logged in.
With your Log-In you can save your favorite events to you calendar and give RSVP to certain events.
No email in your mailbox? Please check your spam folder or try again.
It seems you haven't registered yet!
Register now and become part of the event and the global Falling Walls Community. We will send you news about this and future events and keep you updated about the most exciting breakthroughs in science.
You can withdraw your consent at any time free of charge and without giving reasons.
Enter your email for free registration or login
Simply enter your email address to sign up for free for the event or log in to your account. You will directly receive an email allowing you to log in without a password.
Login failed
You want to login with an account which needs advanced authentification via password. Please use the regular login interface for this email address or register with a different email address for participating in the summit passwordless.
Metabolomic Technologies is developing advanced metabolomic-based diagnostic tests for management of chronic disease or high value diagnostics. Metabolomics refers to the systematic identification and quantification of the small molecule metabolic products (the metabolome) of a biological system.
The company’s lead product, PolypDxTM, is a highly sensitive diagnostic for early stage detection of colorectal cancer. It is the first and only urine-based test with a high sensitivity for detecting adenomatous polyps, the precursor to colorectal cancer.
DAVID CHANG, METABOLOMIC TECHNOLOGIES
Marija Petrovic, UNIVERSITY OF ALBERTA
Worldwide, colorectal cancer is the third most common cancer and is a major cancer killer. It is considered to be preventable, with 76-90% of cases being identifiable at the precancerous adenomatous polyp stage via periodic surveillance. PolypDx provides healthcare professionals with a new test for early screening and detection, enabling the timely removal of adenomatous, precancerous polyps before they progress to colorectal cancer. MTI’s test was developed in a Canadian 1000-patient clinical trial and validated in trials in both Alberta, Canada and Hangzhou, China. It detects specific biomarkers in the urine, which are indicators of the presence of precancerous polyps.
Unlike current fecal-based screening tests, PolypDx requires only a small urine sample and demonstrated higher sensitivity to detect adenomatous polyps. Through research and development, the test was optimised from a research-based, NMR test to a mass-spectometry (LC/MS) platform, which is more widely available commercially. Metabolomic Technologies is positioning their test to become the new standard of care for colorectal cancer prevention and screening.
We use cookies and other technologies to collect data about your use of our site and about your browser, device and location. We process this data to help us understand how the site is used and to personalize our content and the advertising you see on this and other sites we also share this data with advertising, social media and analytics partners for the same purposes. By choosing “Accept All” you agree that we store cookies on your device and process the data for the aforementioned purposes . You may revoke your consent at any time by choosing the respective settings. For more information on the processing of personal data and what specific services we use see our Privacy Policy
Privacy Preference Center
We use cookies and other technologies to collect data about your use of our site and about your browser, device and location. We process this data to help us understand how the site is used and to personalize our content and the advertising you see on this and other sites we also share this data with advertising, social media and analytics partners for the same purposes. By choosing “Accept All” you agree that we store cookies on your device and process the data for the aforementioned purposes . You may revoke your consent at any time by choosing the respective settings. For more information on the processing of personal data and what specific services we use see our Privacy Policy
Necessary Cookies
These cookies are required to provide you with our site and its functions. Since storing these cookies is necessary for the provision of our site and its functions, you cannot disable them. If you block these cookies via you browser settings our site may not function properly.
Analyse Cookies
These cookies enable us to use website analytics in order to improve our site or provide you with personalized content. They may be set by us or by third party providers whose services we have added to our pages.
Marketing Cookies
These cookies enable us to use online marketing and advertising in order to provide you on this or on other sites with personalized advertisement. They may be set by us or by third party providers whose services we have added to our pages.
